Pages
Home
Investments
Transaction Advisory
Investment Research and Business Due Diligence
Contact Us
Wednesday, January 30, 2013
Mitsubishi Tanabe gets Market Authorization for BindRen for treatment of Hyperphosphatemia
Mitsubishi Tanabe European subsidiary Mitsubishi Pharma Europe limited has received Market Authorization for BindRen (colestilan) for treatment of Hyperphosphatemia in patients with Chronic Kidney disease Stage V receiving haemodialysis or peritoneal dialysis.
In patients with chronic kidney disease phosphorus is not sufficiently excreted from the body and is thus accumulated over time leading to hyperphosphatemia. In Phase 2 / Phase 3 trials, Bindren demonstrated reduction in serum phosphorus and calcium phosphate levels.
In Japan, the product has been marketed since 1999 under the brand name "CHOLEBINE for the treatment of hypercholestorolemia.
Enter your email address:
Delivered by
FeedBurner
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment